微生物群在非酒精性脂肪性肝病发病机制、诊断和治疗中的作用的最新进展。
An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment.
作者信息
Mouzaki Marialena, Loomba Rohit
机构信息
Steatohepatitis Center, Cincinnati Children's Hospital Medical Center, University of Cincinnati.
NAFLD Research Center, Division of Gastroenterology, Department of Medicine, University of California at San Diego.
出版信息
Curr Treat Options Gastroenterol. 2020 Jun;18(2):270-280. doi: 10.1007/s11938-020-00290-2. Epub 2020 May 2.
Abstract
The microbiome was originally postulated to contribute to the pathogenesis of NAFLD when the first studies of dysbiosis in NAFLD were reported. Since then, a number of studies have investigated this finding further, in order to discern whether the dysbiosis is the result of the metabolic dysregulation seen with NAFLD or a contributor to the pathogenesis of this condition.
摘要
当首次报道非酒精性脂肪性肝病（NAFLD）中微生物群失调的研究时，微生物群最初被假定与NAFLD的发病机制有关。从那时起，许多研究进一步调查了这一发现，以确定微生物群失调是NAFLD所见代谢失调的结果，还是这种疾病发病机制的一个促成因素。
相似文献
1
An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment.微生物群在非酒精性脂肪性肝病发病机制、诊断和治疗中的作用的最新进展。
Curr Treat Options Gastroenterol. 2020 Jun;18(2):270-280. doi: 10.1007/s11938-020-00290-2. Epub 2020 May 2.
2
Non-alcoholic fatty liver and the gut microbiota.非酒精性脂肪肝与肠道微生物群
Mol Metab. 2016 Jun 14;5(9):782-94. doi: 10.1016/j.molmet.2016.06.003. eCollection 2016 Sep.
3
Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease.系统评价：微生物失调与非酒精性脂肪性肝病。
Aliment Pharmacol Ther. 2015 Nov;42(9):1051-63. doi: 10.1111/apt.13376. Epub 2015 Aug 24.
4
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.肠道微生物群驱动的肠道血管屏障破坏是非酒精性脂肪性肝炎发展的前提。
J Hepatol. 2019 Dec;71(6):1216-1228. doi: 10.1016/j.jhep.2019.08.005. Epub 2019 Aug 13.
5
Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.与儿童非酒精性脂肪性肝病患者的脂肪性肝炎和中重度纤维化相关的微生物组特征。
Gastroenterology. 2019 Oct;157(4):1109-1122. doi: 10.1053/j.gastro.2019.06.028. Epub 2019 Jun 27.
6
Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者的肠道菌群失调。
Hepatobiliary Pancreat Dis Int. 2017 Aug 15;16(4):375-381. doi: 10.1016/S1499-3872(17)60019-5.
7
Intestinal microbiota and nonalcoholic steatohepatitis.肠道微生物群与非酒精性脂肪性肝炎
Curr Opin Gastroenterol. 2017 May;33(3):128-133. doi: 10.1097/MOG.0000000000000349.
8
Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?益生菌在非酒精性脂肪性肝病中的作用：肠道微生物组是否重要？
Nutrients. 2019 Nov 19;11(11):2837. doi: 10.3390/nu11112837.
9
Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病中的胆汁酸与肠道菌群失调
PLoS One. 2016 May 20;11(5):e0151829. doi: 10.1371/journal.pone.0151829. eCollection 2016.
10
Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.台湾经活检证实的非酒精性脂肪性肝病患者的肠道微生物失调：一项横断面研究。
Nutrients. 2020 Mar 19;12(3):820. doi: 10.3390/nu12030820.
引用本文的文献
1
Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease.基于肠道微生物组的机器学习特征用于诊断酒精相关和代谢功能障碍相关脂肪性肝病。
Sci Rep. 2024 Jul 12;14(1):16122. doi: 10.1038/s41598-024-60768-2.
2
Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway.黄芩汤通过激活 Sirt1/NF-κB 通路缓解非酒精性脂肪性肝病的脂代谢紊乱和胰岛素抵抗。
World J Gastroenterol. 2023 Aug 21;29(31):4744-4762. doi: 10.3748/wjg.v29.i31.4744.
3
Ecological shifts of salivary microbiota associated with metabolic-associated fatty liver disease.与代谢相关脂肪性肝病相关的唾液微生物群落的生态转变。
Front Cell Infect Microbiol. 2023 Feb 14;13:1131255. doi: 10.3389/fcimb.2023.1131255. eCollection 2023.
4
NASH and the Gut Microbiome: Implications for New Therapies.非酒精性脂肪性肝炎与肠道微生物群：对新疗法的启示
Clin Liver Dis (Hoboken). 2022 Jan 28;19(3):97-100. doi: 10.1002/cld.1170. eCollection 2022 Mar.
5
Discovery of farnesoid X receptor and its role in bile acid metabolism.法尼酯X受体的发现及其在胆汁酸代谢中的作用。
Mol Cell Endocrinol. 2022 May 15;548:111618. doi: 10.1016/j.mce.2022.111618. Epub 2022 Mar 11.
6
The gut microbiota instructs the hepatic endothelial cell transcriptome.肠道微生物群指导肝内皮细胞转录组。
iScience. 2021 Sep 10;24(10):103092. doi: 10.1016/j.isci.2021.103092. eCollection 2021 Oct 22.
本文引用的文献
1
Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae.由高产酒精肺炎克雷伯菌引起的脂肪肝疾病
Cell Metab. 2019 Dec 3;30(6):1172. doi: 10.1016/j.cmet.2019.11.006.
2
Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study.非酒精性脂肪性肝病患者肠道微生物群中粪杆菌丰度显著下降：一项基于大 BMI 和性别匹配人群的研究。
Hepatol Int. 2019 Nov;13(6):748-756. doi: 10.1007/s12072-019-09987-8. Epub 2019 Sep 12.
3
High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study.高效多菌株益生菌改善非酒精性脂肪性肝病（NAFLD）的肝脏组织学：一项随机、双盲、概念验证研究。
BMJ Open Gastroenterol. 2019 Aug 7;6(1):e000315. doi: 10.1136/bmjgast-2019-000315. eCollection 2019.
4
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.肠道微生物群驱动的肠道血管屏障破坏是非酒精性脂肪性肝炎发展的前提。
J Hepatol. 2019 Dec;71(6):1216-1228. doi: 10.1016/j.jhep.2019.08.005. Epub 2019 Aug 13.
5
Circulating microbiota-derived metabolites: a "liquid biopsy?循环微生物衍生代谢物：一种“液体活检”？
Int J Obes (Lond). 2020 Apr;44(4):875-885. doi: 10.1038/s41366-019-0430-0. Epub 2019 Aug 6.
6
A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease.涉及肠道微生物群、循环胆汁酸和肝脏代谢基因的网络，可预防非酒精性脂肪性肝病。
Mol Nutr Food Res. 2019 Oct;63(20):e1900487. doi: 10.1002/mnfr.201900487. Epub 2019 Jul 30.
7
Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention.深入了解肠道微生物群在非酒精性脂肪性肝病中不断演变的作用：治疗干预的理论依据和前景
Therap Adv Gastroenterol. 2019 Jun 23;12:1756284819858470. doi: 10.1177/1756284819858470. eCollection 2019.
8
Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.与儿童非酒精性脂肪性肝病患者的脂肪性肝炎和中重度纤维化相关的微生物组特征。
Gastroenterology. 2019 Oct;157(4):1109-1122. doi: 10.1053/j.gastro.2019.06.028. Epub 2019 Jun 27.
9
Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.非酒精性脂肪性肝病的肠道微生物组靶向治疗：系统评价、荟萃分析和荟萃回归。
Am J Clin Nutr. 2019 Jul 1;110(1):139-149. doi: 10.1093/ajcn/nqz042.
10
Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.三甲胺 N-氧化物通过调节胆汁酸代谢和抑制法尼醇 X 受体信号通路加重非酒精性脂肪性肝病中的肝脂肪变性。
Mol Nutr Food Res. 2019 Sep;63(17):e1900257. doi: 10.1002/mnfr.201900257. Epub 2019 May 22.
Zotero 插件